<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04013620</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0062</org_study_id>
    <nct_id>NCT04013620</nct_id>
  </id_info>
  <brief_title>CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction</brief_title>
  <acronym>TRANSIBELA</acronym>
  <official_title>CNI Transient Replacement by Belatacept From 3 to 12 Months Post Transplantation in Patients With Early Graft Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Calcineurin inhibitors (CNI) remain the standard treatment in renal transplantation to
      prevent rejection. Currently the main limitation of kidney transplantation is the occurrence
      of chronic graft dysfunction due to the CNI nephrotoxicity. Thus, strategies to minimize or
      stop CNI have been developed as belatacept, a fusion protein (CTLA4-Ig) blocking the ligand
      of the main CD28 costimulatory molecule. In the original phase III trial, used de novo in
      combination with MMF (without CNI) belatacept allowed to obtain a better renal function as
      soon as 1 year and a better graft and patient survival after 7 years. Despite these excellent
      results, belatacept has not become the gold standard due to a higher incidence of early
      rejection. In addition, belatacept is not covered by the french social security policy,
      because benefits are considered insufficient with respect to the cost. Patients with poor
      early graft function are a preferred indication of belatacept. It is then used instead of CNI
      at 3 months post-transplant allowing to improve kidney function without over-risk of
      rejection. Currently after conversion, belatacept is maintained indefinitely due to the
      supposed CNI chronic nephrotoxicity. However this one is more and more questionable. Thus,
      the investigators assume that in patients with poor function at 3 months posttransplantation
      the belatacept's benefit could be obtained by a transient replacement of CNI by belatacept
      from 3 to 12 months post-transplantation. It is the feasibility of this strategy and its
      medico-economic impact that the investigators wish to study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard maintenance regimen in renal transplantation combines calcineurin inhibitor
      (CNI: ciclosporin or tacrolimus) and anti-metabolite drugs (mycophenolate mofetil (MMF) or
      mycophenolic acid (MPA)). CNI in the 1980s made kidney transplantation possible by
      drastically reducing acute rejection rates in the first year. Currently the main limitation
      of kidney transplantation is the occurrence of chronic graft dysfunction. While half of
      patients die with a functional graft, the other half return to dialysis and require
      retransplantation. Paradoxically, CNI has been identified as a leading cause of chronic graft
      dysfunction. Indeed, these molecules are nephrotoxic both : acutely and transitory due to a
      vasoconstrictor effect that modulates intra-renal hemodynamic and chronically due to
      extensive fibrosis. In the late 1990s, with the development of a new class of
      immunosuppressants, mammilian target of rapamycin (mTor) inhibitors (sirolimus and
      everolimus), CNI-free protocols were developed. The results were disappointing due in part to
      the undesirable effects of these treatments and secondly to the occurence of chronic
      rejections related to the appearance of Donor Specific Antibody (DSA) antibodies.

      Finally in the mid-2000s belatacept is a fusion protein (CTLA4-Ig) blocking the ligands of
      the main costimulatory molecule (CD28) emerged. In the Phase III princeps assay (BENEFIT),
      this molecule was used as a maintenance treatment following transplantation (de novo) in
      combination with MMF (without CNI). Compared to the control group with CNI, patients
      receiving belatacept had better renal function from 1 year and after 7 years survival (graft
      and patient) were better. These benefits were attributed, on the one hand, to the absence of
      CNI and, on the other hand, to a very good control of the alloimmune response demonstrated by
      a lower incidence of DSA in the belatacept group.

      Despite these excellent results, belatacept has not become the gold standard in renal
      transplantation for two main reasons. First, when it is used de novo (as in BENEFIT), there
      is a significant incidence of early rejection, known as &quot;costimulation blockade resistant&quot;.
      The second issue is medico-economic. Indeed, to date and despite the accumulation of
      favorable data, in France and in most countries, belatacept has marketing authorization but
      is not supported by social security policy due to benefits regarded as insufficient with
      respect to the cost (related to the IV administration requiring hospital environment every
      month).

      Consequently, it is important to precise which recipients may benefit more from this
      molecule. Patients, often elderly, with poor early function of the graft due to the poor
      quality of a marginal / &quot;extended criteria&quot; donor, are a good indication of belatacept not
      used de novo but after 3 months instead of CNI. This conversion most often allows to
      significantly improve the renal function of these patients to a much more acceptable level
      which remains stable beyond and without cost in terms of rejection (probably because of the
      time interval with the transplant). In this situation, several series reported success rates
      ranging from 80 to 100% with a rejection incidence between 0 and 20%. Failures are most often
      due to patients with non-primary graft function.

      Currently after the conversion, belatacept is always maintained indefinitely most often in
      association with MMF. This usage generates significant costs and in fact, limits the access
      of belatacept for other patients. This practice is based on the dominant idea that chronic
      nephrotoxicity of CNI is the cause of chronic graft dysfunction.

      However, while reversible acute toxicity, mediated by hemodynamic changes in intra-renal
      vascularization, is undeniable, the importance and even the reality of chronic, cumulative,
      irreversible CNI toxicity has been questioned during the last decade, while the importance of
      chronic anti-donor antibody (DSA) rejection to explain chronic graft dysfunction was
      demonstrated. The chronic toxicity of CNI is probable when high doses are necessary to
      prevent rejection during the first year but uncertain beyond.

      Thus, the investigators assume that in patients with poor graft function at 3 months
      post-transplantation most of the benefit of belatacept could be obtained by a transient
      replacement of CNI from 3 to 12 months post-transplantation.

      Indeed, in these often elderly patients, who have most often received an &quot;extended criteria&quot;
      graft (derived from a marginal donor), presenting chronic lesions, CNI-induced intra-renal
      vasoconstriction could more easily evolve to irreversible lesions in the context of
      ischemia-reperfusion inherent in the graft itself. At 1 year after transplantation the
      reintroduction of CNIs at minimized doses could only moderately alter the renal function
      allowing to maintain them at long term.

      The purpose of this study is to demonstrate the feasibility of this transient treatment
      strategy (from 3 to 12 months post transplantation) in patients with poor function at 3
      months.

      From 3 months post-transplantation, patients will receive for 9 months (phase 1) a treatment
      with belatacept allowing to stop CNI. Then CNI will be reintroduced (phase 2) with a
      follow-up period of 6 months which will make it possible to judge the feasibility of this
      strategy.

      Belatacept is the only biotherapy introduced successfully in transplantation. But this
      treatment, because of the limitations raised, has not yet found a definite place. Our project
      is to study a practical question: can the investigators stop belatacept after having
      introduced it early in the context of an early dysfunction while preserving the benefits. The
      decisive contribution of this study would be to prove the concept of a transient treatment by
      belatacept which has not been reported. The medico-economic consequences would be major, the
      cost of a long-term treatment by belatacept, especially because of its administration in
      hospital, being much higher than that of a conventional treatment.

      A secondary objective is to measure by flow cytometry the evolution of the absolute and
      relative amount of regulatory T lymphocytes. Indeed, the negative effect of belatacept on
      this essential lymphocyte population remains very controversial.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">July 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 9, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of a transient replacement of CNIs by belatacept in renal transplant patients with early graft dysfunction. Creatinine clearance did not decrease by more than 25% from the cessation of belatacept 6 months after reintroduction of CNI.</measure>
    <time_frame>Month 15</time_frame>
    <description>Feasibility was defined by preserved renal function and good tolerance 6 months after reintroduction of CNI.
Renal function was defined as preserved if creatinine clearance (according to Chronic Kidney Disease - Epidemiology Collaboration (CKD-EPI)) did not decrease by more than 25% from the cessation of belatacept.
The good tolerance of CNI was defined by the absence of complications leading to the cessation of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effectiveness of belatacept treatment on renal function (creatinine clairance) and to prevent rejection. (Number of rejection Ã©pisodes)</measure>
    <time_frame>Day 0, Month 3, Month 6, Month 9</time_frame>
    <description>Longitudinal monitoring of renal function (Day 0, Month 3, Month 6, Month 9) and collection of rejection episodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the tolerance of treatments (belatacept during phase 1 and CNI during phase 2). Number of adverse events.</measure>
    <time_frame>Month 3, Month 6, Month 9, Month 12, Month 15</time_frame>
    <description>Collection of infectious episodes and neoplasias</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the cost of care (from 3 months to 18 months post-transplant) and compare with the cost of a theoretical arm benefiting from belatacept continuously and a theoretical arm benefiting from CNIs continuously.</measure>
    <time_frame>Month 3, Month 6, Month 9, Month 12, Month 15</time_frame>
    <description>Number of care resources used for treatment : number of medication, number of hospitalization, number of transportation, number of consultations, number of medical procedures, possible home help and associated costs over 15 months of follow-up, and collection of cost data in the literature for the comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the evolution of the quality of life during the 15 months of follow-up and compare it to a theoretical arm benefiting from belatacept continuously, and a theoretical arm benefiting from CNIs continuously: generic EuroQol-5D scale</measure>
    <time_frame>Month 3, Month 6, Month 9, Month 12, Month 15</time_frame>
    <description>Measurement of quality of life scores (generic EuroQol-5D scale) every 3 months for 15 months and collection of quality of life data in the literature for comparison.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the impact of CNI and belatacept on the amount of regulatory T lymphocytes (+ constitution of a collection).</measure>
    <time_frame>Month 3, Month 6, Month 9, Month 12, Month 15</time_frame>
    <description>Flow cytometry measurement of the absolute and relative amount of regulatory T lymphocytes (cluster of differentiation 3 + / cluster of differentiation 4 + / cluster of differentiation 25 + / cluster of differentiation127low / FOXP3 +)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Chronic Kidney Failure</condition>
  <arm_group>
    <arm_group_label>transient belatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept 250 Milligram Intravenous Powder for Solution</intervention_name>
    <description>Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15 and 30 then every months) and CNI withdrawal.
Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)</description>
    <arm_group_label>transient belatacept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult older than 18 years old.

          -  transplantation of a deceased or living donor kidney (non-human leukocyte
             antigen(HLA)-identical) with blood type (ABO) compatibility

          -  no contraindication to the protocol graft biopsy (10 weeks post transplant)

          -  treatment by CNI / MPA +/- prednisone

          -  renal function estimated by creatinine clearance according to CKD-EPI &lt;30 ml / min /
             1.73m2.

          -  having no difficulty in understanding and communicating with the investigator and his
             representatives.

          -  benefiting from a Social Security policy.

          -  results of the 10-week post-transplant renal biopsy finding no rejection or BK virus
             (member of the polyomavirus family) nephropathy, no recurrence, no thrombotic
             microangiopathy, no cortical necrosis.

          -  Seropositivity for Epstein-Barr virus (EBV)

          -  negative pregnancy test and agreement on the use of effective contraception throughout
             the study

        Exclusion Criteria:

          -  Presence of Donor Specific Antibody during kidney transplant or appeared at 3 months
             post-transplantation.

          -  seropositivity for HIV

          -  another history of other solid organ transplants (outside the kidney)

          -  primary non-function (persistence of a need for dialysis at 3 months
             post-transplantation)

          -  participation in progress to another interventional clinical study

          -  any clinical condition that the investigator considers incompatible with the course of
             the study.

          -  contraindication to belatacept.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Simon VILLE, PH</last_name>
    <phone>0240087453</phone>
    <email>simon.ville@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Simon VILLE</last_name>
      <phone>0240087453</phone>
      <email>simon.ville@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>SIMON VILLE, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Vincenti F. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med. 2016 Jun 30;374(26):2600-1. doi: 10.1056/NEJMc1602859.</citation>
    <PMID>27355541</PMID>
  </reference>
  <results_reference>
    <citation>Le Meur Y, Aulagnon F, Bertrand D, Heng AE, Lavaud S, Caillard S, Longuet H, Sberro-Soussan R, Doucet L, Grall A, Legendre C. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors. Am J Transplant. 2016 Jul;16(7):2181-6. doi: 10.1111/ajt.13698. Epub 2016 Mar 2.</citation>
    <PMID>26718625</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>July 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

